(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 508.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.24%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Mereo Biopharma Group's revenue in 2025 is $500,000.On average, 2 Wall Street analysts forecast MREO's revenue for 2025 to be $51,706,486,260, with the lowest MREO revenue forecast at $40,171,962,402, and the highest MREO revenue forecast at $63,241,010,118. On average, 3 Wall Street analysts forecast MREO's revenue for 2026 to be $54,707,848,916, with the lowest MREO revenue forecast at $29,767,026,398, and the highest MREO revenue forecast at $74,218,694,893.
In 2027, MREO is forecast to generate $95,516,198,841 in revenue, with the lowest revenue forecast at $70,766,292,580 and the highest revenue forecast at $109,776,847,752.